While the specific cause of death for Chad Greenwald isn't provided in the available text, the materials do offer a comprehensive overview of cardiac arrest (CA) and the subsequent brain injury that often occurs. This article will delve into the mechanisms of CA-induced brain injury, current treatment strategies, and future avenues for improving patient outcomes.
Roughly 550,000 people in the USA suffer cardiac arrest (CA) annually. Despite improvements in advanced cardiac life support (ACLS), basic cardiac life support (BCLS), resuscitation protocols, and training, only 11.5% of out-of-hospital cardiac arrest (OHCA) patients treated by emergency medical services (EMS) survive until hospital discharge.
Poor neurological outcome is common among CA survivors because CA causes hypoxic-ischemic brain injury (HIBI). HIBI is a complex pathophysiological mechanism of brain damage caused by oxygen deprivation, reduction in cerebral perfusion, and cytotoxicity.
Mechanisms of Brain Injury Following Cardiac Arrest
The pathogenesis of global brain injury secondary to CA is complex. Mechanisms of CA-induced brain injury include ischemia, hypoxia, cytotoxicity, inflammation, and ultimately, irreversible neuronal damage.
CA leads to reduced cerebral blood flow (CBF), initiating a cascade of primary metabolic dysfunction in the neurons and secondary reperfusion injuries to the brain. Cerebral perfusion after CA and resuscitation can be characterized by a gradual, multi-phasic restoration of CBF and cerebral autoregulation over the first 72 h.
Read also: The Life of Chad Everett Harris
Here's a simplified breakdown of the phases:
CARDIAC ARREST EMERGENCY MANAGEMENT, UNCONSCIOUS PULSELESS PATIENT TREATMENT ACLS RHYTHM REVIEW 2021
| Phase | Description |
|---|---|
| Reactive Hyperemia | Initial post-resuscitation increase in blood pressure and CBF. |
| Hypoperfusion | Decrease in CBF that can exacerbate secondary injury. |
| Restoration | Gradual restoration of CBF and cerebral autoregulation. |
The initial post-resuscitation increase in blood pressure and CBF is termed reactive hyperemia. Hypoperfusion can arise as the result of the no-reflow phenomenon (incomplete microvascular filling during reperfusion) and the actions of vasoconstrictors.
Intracellular metabolic and ionic changes are hallmarks of ischemic injury that play an important role in homeostasis and neuronal survival. The primary injury phase of HIBI is characterized by cellular excitotoxicity leading to neuronal and glial cell death.
Evolution of Treatment Guidelines
Over the past decade, there have been multiple modifications to monitoring and treatment guidelines for HIBI secondary to CA. In 2006, the American Academy of Neurology (AAN) proposed a set of prognostic guidelines for CA-induced HIBI, consisting of brain stem reflex assessment, myoclonus status epilepticus 24 h after CA, somatosensory evoked potential (SSEP) 24-72 h after CA, and neuron-specific enolase (NSE) within 24-72 h after CA.
In 2015, the European Resuscitation Council/European Society of Intensive Care Medicine (ERC/ESICM) also adopted a multimodal approach and expanded its guidelines to include targeted temperature management (TTM), sedative clearance, and waiting at least 72 h prior to prognostication to account for delayed neurological recovery.
Read also: "Married to Evil": Chad Graves
Current guidelines suggest avoiding hypotension. More recent studies suggest maintaining elevated MAP following CA to adequately perfuse the brain and maintain optimal CBF in the setting of cerebral dysregulation.
Current and Future Treatment Strategies
Currently, targeted temperature management (TTM) is the leading treatment, with the number of patients needed to treat being ~ 6 in order to improve outcome for one patient. Future avenues of treatment, which may potentially be combined with TTM, include pharmacotherapy, perfusion/oxygenation targets, and pre/postconditioning.
Management of HIBI is mainly focused on limiting secondary injury. Immediately following resuscitation, reperfusion injury causes microvascular dysfunction, hyperoxia, cytotoxicity, inflammatory processes, and cerebral edema.
Understanding cerebral autoregulation is critical for informing optimal MAP targets for CA patients. For example, patients with hypertension exhibit a cerebral autoregulation curve that is shifted to the right, suggesting that hypertensive patients may particularly benefit from higher blood pressure targets after CA.
Read also: Vallow-Daybell Trial: Key Evidence
Popular articles:
tags: #Chad
